Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study.

ABSTRACT:

Background

Oral corticosteroid (OCS) dependence among patients with severe eosinophilic asthma can cause adverse outcomes, including adrenal insufficiency. PONENTE's OCS reduction phase showed that, following benralizumab initiation, 91.5% of patients eliminated corticosteroids or achieved a final dosage ≤5 mg·day^-1 (median (range) 0.0 (0.0-40.0) mg).

Methods

The maintenance phase assessed the durability of corticosteroid reduction and further adrenal function recovery. For ∼6 months, patients continued benralizumab 30 mg every 8 weeks without corticosteroids or with the final dosage achieved during the reduction phase. Investigators could prescribe corticosteroids for asthma exacerbations or increase daily dosages for asthma control deteriorations. Outcomes inclu

SUBMITTER: Menzies-Gow A 

PROVIDER: S-EPMC9791910 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature